Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

FOSINOPRIL SODIUM 10 MG TAB

Fosinopril
$0.1580per EA

Strength

10 mg/1

Manufacturer

Cipla USA Inc.

NDC

69097085605

Classification

Generic

Dosage Form

TABLET

Route

ORAL

Last Updated

4/22/2026

Active Ingredients

FOSINOPRIL SODIUM

Approval Type

Generic (ANDA)

FDA Application

ANDA077222

On Market Since

6/16/2016

Pharmacological Classes

Angiotensin Converting Enzyme Inhibitor
Angiotensin-converting Enzyme Inhibitors

Price History

1W

0.0%

1M

-3.4%

3M

-7.0%

6M

-4.2%

1Y

-4.9%

3Y

-7.1%

5Y

+3.8%

All

+14.1%

Generic Alternatives

No alternatives available

No alternatives found with the same active ingredient, strength, and dosage form.

Related Drugs

Same classification

LISINOPRIL 2.5 MG TABLET
Generic
65862003701•Aurobindo Pharma Limited
$0.0143
per EA
LISINOPRIL 2.5 MG TABLET
Generic
65862003705•Aurobindo Pharma Limited
$0.0143
per EA
LISINOPRIL 2.5 MG TABLET
Generic
65862003799•Aurobindo Pharma Limited
$0.0143
per EA
LISINOPRIL 2.5 MG TABLET
Generic
00591040501•Actavis Pharma, Inc.
$0.0144
per EA
LISINOPRIL 2.5 MG TABLET
Generic
00591040505•Actavis Pharma, Inc.
$0.0144
per EA
LISINOPRIL 2.5 MG TABLET
Generic
23155087601•Heritage Pharmaceuticals Inc.
$0.0144
per EA
LISINOPRIL 2.5 MG TABLET
Generic
23155087605•Heritage Pharmaceuticals Inc.
$0.0144
per EA
LISINOPRIL 2.5 MG TABLET
Generic
31722017201•Camber Pharmaceuticals Inc.
$0.0144
per EA
LISINOPRIL 2.5 MG TABLET
Generic
31722017205•Camber Pharmaceuticals Inc.
$0.0144
per EA
LISINOPRIL 2.5 MG TABLET
Generic
43547035110•Solco Healthcare US LLC
$0.0144
per EA

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy